13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001969764
Total reported value
$191.1M
$191.1M
16 檔
33.0%
In Q3 2025, Propel Bio Management, LLC's U.S. equity holdings reached a combined market value of $191.1M, distributed across 16 disclosed stock positions.
Propel Bio Management, LLC executed strategic sector rebalancing during Q3 2025, establishing 6 new positions while fully exiting 8 holdings and trimming 2 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PAGP | Plains Gp Holdings Lp-cl A | Stock-Energy | 23.23% | -2.86% | — | |
| 2 | ACHV | Achieve Life Sciences Inc | Stock-Other | 11.94% | +6.62% | -38.46% | |
| 3 | AKRO | Akero Therapeutics Inc | Stock-Other | 10.88% | — | — | |
| 4 | MIST | Milestone Pharmaceuticals In | Stock-Other | 10.26% | +2.01% | +186.06% | |
| 5 | APLT | Applied Therapeutics Inc | Stock-Other | 6.83% | — | — | |
| 6 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 6.51% | +0.06% | -40.09% | |
| 7 | ABEO | Abeona Therapeutics Inc | Stock-Other | 5.15% | -0.61% | — | |
| 8 | DCTH | Delcath Systems Inc | Stock-Other | 4.72% | -0.03% | +93.99% | |
| 9 | CLDX | Celldex Therapeutics Inc | Stock-Other | 4.01% | -0.59% | — | |
| 10 | TCRX | Tscan Therapeutics Inc | Stock-Other | 3.52% | — | -7.42% | |
| 11 | CMPS | Compass Pathways PLC | Stock-Other | 2.93% | +1.64% | — | |
| 12 | NKTR | Nektar Therapeutics | Stock-Other | 2.79% | — | — | |
| 13 | JSPR | Jasper Therapeutics Inc | Stock-Other | 2.45% | — | — | |
| 14 | ZVRA | Zevra Therapeutics Inc | Stock-Other | 2.21% | +0.24% | — | |
| 15 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.94% | -2.58% | EXIT | |
| 16 | LONA | Leonabio Inc | Stock-Other | 0.62% | -0.22% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MIST | Milestone Pharmaceuticals In | +8.9% | +186.06% | Add |
| 2 | ACHV | Achieve Life Sciences Inc | +4.3% | -38.46% | Add |
| 3 | DCTH | Delcath Systems Inc | +2.1% | +93.99% | Add |
| 4 | ABEO | Abeona Therapeutics Inc | +1.7% | — | Add |
| 5 | ZVRA | Zevra Therapeutics Inc | +0.6% | — | Add |
| 6 | APLT | Applied Therapeutics Inc | +0.4% | — | Unchanged |
| 7 | TCRX | Tscan Therapeutics Inc | +0.2% | -7.42% | Trim |
| 8 | AKRO | Akero Therapeutics Inc | +0.1% | — | Unchanged |
| 9 | PHAT | Phathom Pharmaceuticals Inc | -1.8% | -40.09% | Trim |
| 10 | PAGP | Plains Gp Holdings Lp-cl A | -8.3% | — | Unchanged |
| 11 | MDGL | Madrigal Pharmaceuticals Inc | — | EXIT | Sold out |
| 12 | RNAGBP | Avidity Biosciences Inc | — | EXIT | Sold out |
| 13 | CLDX | Celldex Therapeutics Inc | — | NEW | New buy |
| 14 | CMPS | Compass Pathways PLC | — | NEW | New buy |
| 15 | NKTR | Nektar Therapeutics | — | NEW | New buy |
| 16 | JSPR | Jasper Therapeutics Inc | — | NEW | New buy |
| 17 | SNDX | Syndax Pharmaceuticals Inc | — | EXIT | Sold out |
| 18 | VRDN | Viridian Therapeutics Inc | — | NEW | New buy |
| 19 | ✓ | Maat Pharma Saca | — | EXIT | Sold out |
| 20 | LONA | Leonabio Inc | — | NEW | New buy |
| 21 | CMPX | Compass Therapeutics Inc | — | EXIT | Sold out |
| 22 | ✓ | Athira Pharma Inc | — | EXIT | Sold out |
| 23 | 72C | Eiger Biopharmaceuticals Inc | — | EXIT | Sold out |
| 24 | ✓ | Chinook Therapeutics Cvr | — | EXIT | Sold out |
According to official SEC Form 13F filings, Propel Bio Management, LLC reported a total U.S. public equity portfolio value of $191.1M across 16 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PAGP, ACHV, AKRO) accounted for 33.0% of total reported equity market value during Q3 2025.
Top New Position Initiated
CLDX
市值: $4.0M
Top Position Liquidated / Trimmed
MDGL
前期市值: $9.9M
During Q3 2025, Propel Bio Management, LLC's top holdings by market value included PAGP (23.2%)、ACHV (11.9%)、AKRO (10.9%). The largest single position, PAGP, represented 23.2% of total portfolio value.
In Q3 2025, Propel Bio Management, LLC made 21 total portfolio adjustments, initiating 6 new buys, adding to 5 positions, trimming 2 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.